أرسل هذا في رسالة قصيرة: Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

  _____      ___     _    _      ___              
 /  ___||   / _ \\  | || | ||   / _ \\    ____    
| // __    | / \ || | || | ||  / //\ \\  |    \\  
| \\_\ ||  | \_/ || | \\_/ || |  ___  || | [] ||  
 \____//    \___//   \____//  |_||  |_|| |  __//  
  `---`     `---`     `---`   `-`   `-`  |_|`-`   
                                         `-`